ube2ia Antibody

What are UBE2 family proteins and what roles do they play in cellular processes?

UBE2 proteins are ubiquitin-conjugating enzymes that play crucial roles in the ubiquitin-proteasome system, which regulates protein degradation and cellular homeostasis. These enzymes are primarily located in the nucleus and at the cell membrane, where they facilitate post-replication repair of UV-damaged DNA . UBE2 family members participate in maintaining genome integrity by interacting with key proteins involved in DNA repair processes, such as Rad18, thereby preventing mutations that could lead to cancer . Different members of the family have distinct functions - for example, UBE2V1 forms a heterodimer with UBE2N to catalyze the synthesis of non-canonical poly-ubiquitin chains linked through Lys-63 . This family of proteins is essential for normal cellular function through their roles in protein homeostasis, DNA repair, and cell signaling pathways.

What types of UBE2 antibodies are available for research applications?

Research-grade UBE2 antibodies come in multiple varieties, each optimized for specific applications. For example, UBE2A/B antibodies like the G-9 clone are available as mouse monoclonal IgG1 kappa light chain antibodies that detect UBE2A/B proteins of mouse, rat, and human origin . These antibodies come in both non-conjugated forms and various conjugated options, including agarose, horseradish peroxidase (HRP), phycoerythrin (PE), fluorescein isothiocyanate (FITC), and multiple Alexa Fluor® conjugates . For UBE2V1, polyclonal antibodies such as 10207-2-AP are available with reactivity to human samples . UBE2O antibodies are offered by multiple suppliers in various formats suitable for different applications . The selection of the appropriate antibody depends on the specific research application, target species, and desired detection method.

What are the primary applications of UBE2 antibodies in laboratory research?

UBE2 antibodies are versatile tools that support multiple research techniques. The UBE2A/B antibody (G-9) has been validated for western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), and enzyme-linked immunosorbent assay (ELISA) . UBE2V1 antibodies such as 10207-2-AP are primarily used for WB and ELISA applications . UBE2O antibodies from various suppliers support applications including WB, IHC-p, ICC, IF, and IP . These techniques allow researchers to study protein expression levels, localization, interactions, and modifications in various experimental systems. The choice of application depends on the specific research question, available sample types, and desired data output.

How do I determine the appropriate antibody dilution for my UBE2 western blotting experiments?

• Begin with the manufacturer's recommended range

• Perform a dilution series (e.g., 1:200, 1:500, 1:1000)

• Select the dilution that provides the best signal-to-noise ratio

• Validate with appropriate positive and negative controls

• Document the optimized conditions for future experiments

This methodological approach ensures reproducible and reliable results while minimizing background and maximizing specific signal detection.

How can I distinguish between UBE2A and UBE2B when using antibodies that recognize both proteins?

Distinguishing between UBE2A and UBE2B when using antibodies that recognize both proteins (such as the UBE2A/B antibody G-9) requires additional experimental approaches since these proteins share significant sequence homology. To differentiate between them:

• Molecular Weight Analysis: Although similar, UBE2A and UBE2B may show slight differences in molecular weight that can be detected using high-resolution SDS-PAGE.

• Isoform-Specific Antibodies: When available, use antibodies that specifically target unique regions of UBE2A or UBE2B.

• RNA Interference (RNAi): Perform knockdown experiments using siRNAs specific to either UBE2A or UBE2B, followed by western blotting with the UBE2A/B antibody. The reduction in band intensity will indicate which protein was knocked down.

• Immunoprecipitation Followed by Mass Spectrometry: Use the UBE2A/B antibody for immunoprecipitation, then analyze the precipitated proteins by mass spectrometry to identify peptides unique to either UBE2A or UBE2B.

• Genetic Models: Utilize UBE2A or UBE2B knockout models where available, which will show absence of the respective protein.

This multi-faceted approach provides more definitive identification than relying solely on an antibody that recognizes both proteins .

What are the critical considerations for preserving UBE2 protein integrity during sample preparation for immunological techniques?

Preserving UBE2 protein integrity during sample preparation is crucial for accurate experimental results. Consider the following methodological approaches:

• Protease and Phosphatase Inhibitors: UBE2 proteins are susceptible to degradation, so include a comprehensive protease inhibitor cocktail in all lysis buffers. Since phosphorylation can affect antibody recognition, phosphatase inhibitors should also be included.

• Temperature Control: Process samples on ice to minimize protein degradation and maintain UBE2 protein structure.

• Gentle Lysis Conditions: Use non-denaturing lysis buffers for applications requiring native protein conformation (e.g., immunoprecipitation), and avoid excessive sonication or mechanical disruption.

• Reducing Agents: Include reducing agents like DTT or β-mercaptoethanol in sample buffers to maintain the integrity of UBE2 proteins, which may contain critical cysteine residues.

• Storage Conditions: For UBE2V1 antibody, the recommended storage is at -20°C, where it remains stable for one year after shipment. Aliquoting is unnecessary for -20°C storage when using the storage buffer containing PBS with 0.02% sodium azide and 50% glycerol at pH 7.3 .

• Sample Processing Timing: Minimize the time between sample collection and analysis to prevent protein degradation and modification.

These considerations help maintain the native state and activity of UBE2 proteins, ensuring more reliable and reproducible experimental outcomes.

How can I evaluate UBE2 enzyme activity in cells following immunodetection?

Evaluating UBE2 enzyme activity after immunodetection requires specialized approaches that go beyond simple protein detection. A comprehensive methodology includes:

• In Vitro Ubiquitination Assays: Following immunoprecipitation with UBE2 antibodies, the precipitated proteins can be tested for ubiquitination activity using purified ubiquitin, E1 enzymes, and ATP. The formation of poly-ubiquitin chains can be detected by western blotting.

• Heterodimer Activity Assessment: For UBE2V1, which has no ubiquitin ligase activity on its own but forms an active heterodimer with UBE2N, co-immunoprecipitation followed by activity assays can determine functional heterodimer formation .

• Cellular Ubiquitination Profiles: Comparing ubiquitination profiles in cells with normal versus depleted or inhibited UBE2 proteins can reveal substrates and functional impacts.

• Reporter Assays: Using fluorescent ubiquitin reporters to monitor real-time ubiquitination in cells with manipulated UBE2 levels.

• Correlation with DNA Repair Capacity: Since UBE2A/B facilitate postreplication repair of UV-damaged DNA , measuring DNA repair capacity following UBE2A/B manipulation can serve as a functional readout.

This multi-pronged approach provides a more complete understanding of UBE2 enzyme functionality beyond mere protein presence or abundance.

What are the best approaches for studying the interaction between UBE2 proteins and their binding partners?

Studying UBE2 protein interactions requires specialized techniques to capture both stable and transient associations. The following methodological approaches are recommended:

• Co-Immunoprecipitation (Co-IP): UBE2A/B antibodies like G-9 are validated for immunoprecipitation and can be used to pull down UBE2 proteins along with their binding partners . Similarly, UBE2O antibodies from multiple suppliers have been validated for IP applications .

• Proximity Ligation Assay (PLA): This technique can detect protein interactions in situ with high sensitivity using UBE2 antibodies in combination with antibodies against suspected binding partners.

• Bimolecular Fluorescence Complementation (BiFC): By tagging UBE2 proteins and potential partners with complementary fragments of a fluorescent protein, interactions can be visualized in living cells.

• FRET/FLIM Analysis: Using fluorescently labeled antibodies or fusion proteins to detect energy transfer between closely associated proteins.

• Yeast Two-Hybrid Screening: For discovering novel interaction partners of UBE2 proteins.

• Mass Spectrometry Following IP: For unbiased identification of the interactome.

For example, UBE2A/B proteins interact with key proteins involved in DNA repair processes, such as Rad18 . The UBE2V1-UBE2N heterodimer has been well-characterized and catalyzes the synthesis of non-canonical poly-ubiquitin chains linked through Lys-63 . These interactions are critical for understanding the functional roles of UBE2 proteins in various cellular processes.

What are the optimal fixation and permeabilization methods for detecting UBE2 proteins in immunofluorescence studies?

Optimizing fixation and permeabilization methods is critical for preserving UBE2 protein epitopes while allowing antibody access. The following protocol is recommended for UBE2 immunofluorescence studies:

• Fixation Options:

  • For preserving protein localization: 4% paraformaldehyde in PBS for 15 minutes at room temperature

  • For improved epitope access: methanol fixation at -20°C for 10 minutes, particularly useful for nuclear UBE2 proteins

• Permeabilization Methods:

  • For paraformaldehyde-fixed cells: 0.1-0.5% Triton X-100 in PBS for 5-10 minutes

  • For methanol-fixed cells: additional permeabilization is typically unnecessary

• Blocking Conditions:

  • 5% normal serum (from the species in which the secondary antibody was raised) in PBS with 0.1% Tween-20 for 1 hour at room temperature

• Antibody Incubation:

  • Primary antibody: UBE2A/B antibody (G-9) has been validated for immunofluorescence (IF), and conjugated versions (FITC, PE, various Alexa Fluor conjugates) are available for direct detection

  • Secondary antibody: Choose appropriate fluorophore-conjugated antibodies based on your microscopy setup

• Nuclear Counterstaining:

  • DAPI or Hoechst at appropriate dilutions to visualize nuclei, where UBE2A/B proteins are primarily located

This methodological approach facilitates the detection of UBE2 proteins in their native cellular context while maintaining their subcellular localization.

How should I optimize western blotting protocols for detecting low-abundance UBE2 family proteins?

Detecting low-abundance UBE2 family proteins by western blotting requires specific optimizations to enhance sensitivity without increasing background:

• Sample Preparation Enhancements:

  • Increase protein loading (up to 50-100 μg per lane)

  • Concentrate proteins using immunoprecipitation before western blotting

  • Enrich for nuclear fractions when detecting nuclear UBE2 proteins

• Gel and Transfer Optimizations:

  • Use gradient gels (4-20%) for better resolution

  • Optimize transfer conditions: lower voltage transfers (30V) overnight at 4°C can improve transfer efficiency of challenging proteins

  • Use PVDF membranes (0.2 μm pore size) for enhanced protein binding and sensitivity

• Blocking and Antibody Incubations:

  • For UBE2V1 antibody (10207-2-AP), the recommended dilution range is 1:200-1:1000 for western blotting

  • Extend primary antibody incubation to overnight at 4°C

  • Consider signal enhancement systems (biotinylated secondary antibodies with streptavidin-HRP)

  • UBE2A/B antibody (G-9) is available as HRP-conjugated (sc-365507 HRP) which can eliminate secondary antibody steps and reduce background

• Detection Enhancements:

  • Use high-sensitivity ECL substrates with long exposure times

  • Consider digital imaging systems with accumulation mode for weak signals

• Controls and Validation:

  • Include positive controls with known expression of the target UBE2 protein

  • Consider using recombinant UBE2 proteins as standards for quantification

These methodological refinements significantly improve the detection of low-abundance UBE2 family members while maintaining specificity.

What are the recommended protocols for multiplexing UBE2 detection with other proteins of interest?

Multiplexing UBE2 detection with other proteins requires careful planning to avoid antibody cross-reactivity and signal interference. The following methodological approach is recommended:

• Antibody Selection Considerations:

  • Choose primary antibodies from different host species (e.g., mouse anti-UBE2A/B with rabbit anti-target protein)

  • Alternatively, use directly conjugated primary antibodies with different fluorophores

  • Confirm antibody specificity before multiplexing experiments

• Sequential Immunodetection for Western Blotting:

  • For proteins with similar molecular weights: strip and reprobe membranes sequentially

  • For proteins with distinct molecular weights: cut membranes horizontally and probe separately

  • UBE2A/B antibody (G-9) conjugated to HRP (sc-365507 HRP) can be used in one channel

• Fluorescent Multiplexing in Western Blots:

  • Use secondary antibodies with distinct fluorophores

  • Analyze with multi-channel fluorescent imaging systems

  • Available UBE2A/B antibody conjugates include FITC, PE, and various Alexa Fluor options

• Immunofluorescence Multiplexing Protocol:

  • Primary antibody cocktail: combine antibodies at optimal dilutions

  • Secondary antibody cocktail: use spectrally distinct fluorophores

  • Include appropriate controls for each antibody separately

• Flow Cytometry Multiplexing:

  • UBE2A/B antibody is available in PE and FITC conjugated forms

  • Combine with antibodies labeled with complementary fluorophores

  • Perform proper compensation controls

These protocols enable simultaneous detection of UBE2 family proteins with other proteins of interest, facilitating studies of protein co-localization and co-expression.

How can I address non-specific binding issues when using UBE2 antibodies?

Non-specific binding is a common challenge when working with UBE2 antibodies. The following methodological approaches can help resolve this issue:

• Antibody Validation and Selection:

  • Choose well-validated antibodies like UBE2A/B Antibody (G-9), which has been validated for multiple applications

  • Verify specificity through knockout/knockdown experiments or peptide competition assays

• Optimization of Blocking Conditions:

  • Test different blocking agents (BSA, milk, normal serum, commercial blockers)

  • Increase blocking time (2-3 hours at room temperature or overnight at 4°C)

  • Add 0.1-0.3% Tween-20 to blocking and antibody dilution buffers

• Antibody Dilution Refinement:

  • For UBE2V1 antibody, the recommended starting dilution range is 1:200-1:1000, but this should be titrated for each experimental system

  • Perform serial dilutions to identify optimal concentration that maximizes specific signal while minimizing background

• Enhanced Washing Protocols:

  • Increase wash duration and number of washes

  • Use buffers with higher salt concentration (up to 500 mM NaCl) to disrupt weak non-specific interactions

  • Add 0.1-0.5% Tween-20 to wash buffers

• Secondary Antibody Considerations:

  • Use highly cross-adsorbed secondary antibodies

  • Consider secondary antibody-only controls to identify non-specific binding

  • For UBE2A/B detection, conjugated primary antibodies are available that eliminate secondary antibody-related background

This systematic approach can significantly reduce non-specific binding while preserving specific detection of UBE2 family proteins.

How do I interpret contradictory results between different UBE2 antibody applications?

Encountering contradictory results between different applications of UBE2 antibodies (e.g., western blot vs. immunofluorescence) is not uncommon. A methodical approach to resolving these contradictions includes:

• Epitope Accessibility Analysis:

  • Different applications expose different epitopes - for example, UBE2A/B proteins are primarily located in the nucleus and at the cell membrane , but fixation methods may affect epitope accessibility

  • Cross-validate with multiple antibodies targeting different epitopes of the same UBE2 protein

• Protocol-Specific Considerations:

  • Western blotting: Denaturing conditions may expose epitopes hidden in native proteins

  • Immunofluorescence: Fixation and permeabilization may alter protein conformation

  • IP: Antibodies may recognize only native, folded proteins

• Validation Through Complementary Techniques:

  • Confirm protein expression with mRNA analysis (RT-PCR, RNA-seq)

  • Use genetic approaches (overexpression, knockdown, knockout) as controls

  • For UBE2V1, verify results using recombinant protein standards with known molecular weight (20 kDa)

• Documentation of Experimental Conditions:

  • Create a detailed table documenting all variables:

• Literature Reconciliation:

  • Compare your findings with published literature on UBE2 proteins

  • Contact antibody manufacturers for technical support and application-specific guidance

What controls should be included when performing co-immunoprecipitation experiments with UBE2 antibodies?

Co-immunoprecipitation (Co-IP) with UBE2 antibodies requires rigorous controls to ensure reliable and interpretable results. The following controls should be included:

• Input Control:

  • 5-10% of the lysate used for IP should be run as an "input" sample

  • Demonstrates the presence of target proteins in the starting material

• Antibody Specificity Controls:

  • Negative control: IP with non-specific IgG from the same species as the UBE2 antibody

  • Peptide competition: Pre-incubation of UBE2 antibody with immunizing peptide should abolish specific pull-down

  • For UBE2A/B antibody (G-9), which is validated for immunoprecipitation , include IP from cells where UBE2A/B is depleted

• Interaction Specificity Controls:

  • Reverse Co-IP: IP with antibodies against the interacting protein and blot for UBE2

  • IP under different buffer conditions: Increasing salt or detergent concentrations can distinguish strong from weak or non-specific interactions

  • For UBE2V1, which forms a heterodimer with UBE2N , IP with UBE2N antibodies should co-precipitate UBE2V1

• Sample Processing Controls:

  • Non-denatured samples: Maintain native protein structure during lysis

  • Crosslinking controls: If using crosslinkers, include non-crosslinked samples

  • Complete lysis verification: Ensure complete solubilization of membrane-associated UBE2 proteins

• Detection Controls:

  • Secondary antibody-only control: Verifies signal is not due to secondary antibody binding to the IP antibody

  • Clean blot stripping: When reprobing blots, ensure complete removal of previous antibodies

These comprehensive controls help distinguish genuine interactions from artifacts and provide confidence in co-immunoprecipitation results with UBE2 antibodies.

How are UBE2 antibodies being utilized in cancer research and what insights have they provided?

UBE2 antibodies have become valuable tools in cancer research, providing insights into the roles of ubiquitination in tumor development and progression. Recent methodological applications include:

• Expression Profiling in Tumor Samples:

  • UBE2A/B antibodies have been used to evaluate expression levels in various cancer types via immunohistochemistry

  • Altered expression of UBE2 family members correlates with prognosis in certain cancers

  • UBE2A/B proteins facilitate the postreplication repair of UV-damaged DNA, suggesting their role in preventing mutations that could lead to cancer

• Mechanistic Studies of DNA Repair:

  • UBE2A/B antibodies help investigate the interaction of these proteins with Rad18 and other DNA repair proteins

  • Immunofluorescence with UBE2A/B antibodies reveals localization to sites of DNA damage

  • Co-immunoprecipitation experiments identify novel interaction partners in the DNA damage response

• Therapeutic Target Identification:

  • Western blotting with UBE2 antibodies helps evaluate the effects of potential anti-cancer compounds on ubiquitination pathways

  • High-throughput screening assays incorporating UBE2 antibodies identify small molecule inhibitors of specific UBE2 enzymes

• Functional Genomics Approaches:

  • Combining CRISPR-Cas9 gene editing with UBE2 antibody-based protein detection to establish cause-effect relationships

  • Correlation of UBE2 expression with cancer cell resistance to chemotherapy or radiation

These applications have provided insights into how dysregulation of the ubiquitin-proteasome system contributes to cancer development and progression, potentially leading to new therapeutic strategies targeting specific UBE2 family members.

What are the current challenges and emerging solutions in detecting post-translational modifications of UBE2 proteins?

Detecting post-translational modifications (PTMs) of UBE2 proteins presents several challenges due to their transient nature and low abundance. Current challenges and emerging solutions include:

• Challenges in Detecting UBE2 Phosphorylation:

  • Low stoichiometry of phosphorylation events

  • Lack of specific phospho-UBE2 antibodies for many phosphorylation sites

  Emerging Solutions:

  • Phospho-enrichment strategies before antibody-based detection

  • Development of targeted mass spectrometry approaches

  • Phospho-mimetic and phospho-dead mutants for functional studies

• Ubiquitination of UBE2 Enzymes:

  • Self-ubiquitination or ubiquitination by other enzymes affects UBE2 function

  • Difficult to distinguish between catalytic intermediates and regulatory ubiquitination

  Emerging Solutions:

  • Ubiquitin remnant profiling coupled with UBE2 immunoprecipitation

  • Activity-based probes to capture active versus inactive UBE2 enzymes

  • The UBE2V1-UBE2N heterodimer, which catalyzes non-canonical poly-ubiquitin chains linked through Lys-63 , serves as a model for studying ubiquitination dynamics

• Other PTMs (SUMOylation, Acetylation, etc.):

  • Often occur at low abundance

  • May be tissue or stress-specific

  Emerging Solutions:

  • Tandem affinity purification strategies

  • PTM-specific enrichment before western blotting

  • Proximity labeling methods to identify regulators of UBE2 PTMs

• Methodological Approach for Studying UBE2 PTMs:

These emerging solutions are advancing our understanding of how PTMs regulate UBE2 enzyme function and their roles in health and disease.